/
BNGO
$1.17+$0.03 (+2.63%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$13.1M
11M shares
52-week range
$1.06 – $5.50
2% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
5.10%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-4090.83
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M | $10.1M | $8.5M | $18.0M | $27.8M | $36.1M | $30.8M | $28.5M |
| Cost of revenue | $8.7M | $6.8M | $5.7M | $14.1M | $21.9M | $26.6M | $30.4M | $22.3M |
| Gross profit | $3.3M | $3.4M | $2.8M | $3.9M | $5.9M | $9.6M | $380.0K | $6.3M |
| Gross margin | 27.4% | 33.2% | 32.6% | 21.5% | 21.4% | 26.5% | 1.2% | 22.0% |
| R&D | $9.5M | $9.1M | $10.3M | $22.5M | $49.0M | $54.0M | $24.8M | $11.4M |
| Operating income | −$20.4M | −$25.9M | −$38.6M | −$77.1M | −$131.7M | −$215.2M | −$104.0M | −$33.3M |
| EBITDA | −$15.8M | −$26.4M | −$35.6M | −$73.9M | −$120.3M | −$213.6M | −$97.5M | −$16.3M |
| Net income | −$18.5M | −$29.8M | −$41.1M | −$72.4M | −$132.6M | −$232.5M | −$112.0M | −$26.4M |
| Net margin | -154.1% | -294.3% | -483.4% | -402.8% | -476.9% | -643.7% | -364.0% | -92.6% |
| EPS (diluted) | -94089.60 | -71662.20 | -14194.80 | -157.02 | -267.71 | -408.60 | -88.13 | -4.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $32M | $-2.31 | $-2.32–$-2.30 | 1 |
| 2027 | $43M | $-0.97 | $-0.97–$-0.97 | 1 |
| 2028 | $55M | $-0.52 | $-0.52–$-0.52 | 1 |
| 2029 | $67M | $-0.24 | $-0.24–$-0.24 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Bionano Genomics, Inc. Common Stock
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
www.bionano.com- Employees
- 97
- IPO / List date
- Aug 1, 2018
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds BNGO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 48,700 | $57.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-27 | 1-for-60reverse |
| 2023-08-07 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded BNGO yet.
